[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0906104B8 - derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto - Google Patents

derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto

Info

Publication number
BRPI0906104B8
BRPI0906104B8 BRPI0906104A BRPI0906104A BRPI0906104B8 BR PI0906104 B8 BRPI0906104 B8 BR PI0906104B8 BR PI0906104 A BRPI0906104 A BR PI0906104A BR PI0906104 A BRPI0906104 A BR PI0906104A BR PI0906104 B8 BRPI0906104 B8 BR PI0906104B8
Authority
BR
Brazil
Prior art keywords
acid derivative
peptonucleic
compound
pharmaceutical composition
effective amount
Prior art date
Application number
BRPI0906104A
Other languages
English (en)
Inventor
- Yeon Kim Heui
Park Hyun-Jin
Ook Jong-
Cran Kim Mi-
Chung Shin
Original Assignee
Cti Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cti Bio filed Critical Cti Bio
Publication of BRPI0906104A2 publication Critical patent/BRPI0906104A2/pt
Publication of BRPI0906104B1 publication Critical patent/BRPI0906104B1/pt
Publication of BRPI0906104B8 publication Critical patent/BRPI0906104B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

derivado de ácido nuclêico peptídeo, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídeo, método de utilização do derivado de ácido nuclêico peptídico e composto, a presente invenção provê uma nova classe de derivados de ácido nucléico peptídico que demonstram boa penetração celular e forte afinidade de ligação pelo ácido nucléico.
BRPI0906104A 2008-03-14 2009-03-13 derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto BRPI0906104B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2008-23658 2008-03-14
KR20080023658 2008-03-14
KR20080111459 2008-11-11
KR10-2008-111459 2008-11-11
PCT/KR2009/001256 WO2009113828A2 (en) 2008-03-14 2009-03-13 Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid

Publications (3)

Publication Number Publication Date
BRPI0906104A2 BRPI0906104A2 (pt) 2015-06-30
BRPI0906104B1 BRPI0906104B1 (pt) 2021-03-30
BRPI0906104B8 true BRPI0906104B8 (pt) 2021-05-25

Family

ID=41065678

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906104A BRPI0906104B8 (pt) 2008-03-14 2009-03-13 derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto

Country Status (18)

Country Link
US (4) US8680253B2 (pt)
EP (1) EP2268607B9 (pt)
JP (1) JP5620282B2 (pt)
KR (2) KR20090098710A (pt)
CN (1) CN102015628B (pt)
AU (1) AU2009224149B2 (pt)
BR (1) BRPI0906104B8 (pt)
CA (1) CA2715844C (pt)
DK (1) DK2268607T5 (pt)
ES (1) ES2533769T3 (pt)
IL (4) IL207617A (pt)
MX (1) MX2010009687A (pt)
NZ (1) NZ587448A (pt)
PL (1) PL2268607T3 (pt)
PT (1) PT2268607E (pt)
RU (1) RU2564032C2 (pt)
WO (1) WO2009113828A2 (pt)
ZA (1) ZA201005960B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198825B (en) 1987-03-09 1989-12-28 Chinoin Gyogyszer Es Vegyeszet Synergic fungicides
US9234059B2 (en) 2008-07-16 2016-01-12 Outlast Technologies, LLC Articles containing functional polymeric phase change materials and methods of manufacturing the same
US8221910B2 (en) 2008-07-16 2012-07-17 Outlast Technologies, LLC Thermal regulating building materials and other construction components containing polymeric phase change materials
DK2488532T3 (en) 2009-10-16 2018-08-13 Melinta Therapeutics Inc ANTIMICROBIAL COMPOUNDS AND PROCEDURES FOR PREPARING AND USING THE SAME
CN107266470A (zh) * 2009-10-16 2017-10-20 梅琳塔治疗公司 抗微生物化合物和其制备和使用方法
EP3406613A1 (en) * 2009-10-16 2018-11-28 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EA023350B1 (ru) 2009-10-16 2016-05-31 Мелинта Терапьютикс, Инк. Противомикробные соединения, способы их получения и применение
HUE036755T2 (hu) 2011-04-15 2018-07-30 Melinta Therapeutics Inc Antimikrobiális vegyületek, valamint ezek elõállítása és alkalmazása
CN103031337A (zh) * 2012-09-28 2013-04-10 北京吉利奥生物科技发展有限公司 一种小核酸分子快递技术
US10106543B2 (en) 2013-09-09 2018-10-23 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2015035421A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EA201792006A1 (ru) 2015-03-11 2018-04-30 Мелинта Терапьютикс, Инк. Антимикробные соединения и способы их получения и их применение
CA3002073A1 (en) * 2015-10-20 2017-04-27 Sorrento Therapeutics, Inc. Intracellular delivery compounds
CN110312722A (zh) 2016-05-06 2019-10-08 生物验证系统股份公司 抗微生物剂及其制备和使用方法
KR102427575B1 (ko) 2016-08-08 2022-08-01 올리패스 주식회사 안드로겐 수용체 안티센스 올리고뉴클레오타이드
KR102443631B1 (ko) * 2016-09-16 2022-09-15 올리패스 주식회사 Scn9a 안티센스 올리고뉴클레오티드
RU2753517C2 (ru) * 2016-10-11 2021-08-17 Олипасс Корпорейшн Антисмысловые олигонуклеотиды к hif-1-альфа
RU2759022C2 (ru) 2016-11-16 2021-11-08 Академиш Зикенхюис Лейден Вещества для нацеливания на различные выбранные органы или ткани
WO2018122610A1 (en) * 2016-12-30 2018-07-05 Olipass Corporation Exon skipping by peptide nucleic acid derivatives
WO2018127733A1 (en) * 2017-01-06 2018-07-12 Olipass Corporation Snap25 antisense oligonucleotides
US11162104B2 (en) * 2017-01-24 2021-11-02 Olipass Corporation SCN9A antisense pain killer
KR20190011181A (ko) * 2017-07-24 2019-02-01 올리패스 주식회사 티로시나아제 안티센스 올리고뉴클레오티드
KR102236495B1 (ko) * 2017-07-24 2021-04-06 올리패스 주식회사 티로시나아제 안티센스 올리고뉴클레오티드
TWI832851B (zh) * 2018-05-18 2024-02-21 韓商奧利通公司 基質金屬蛋白酶-1之反義寡核苷酸
KR102304280B1 (ko) 2018-08-14 2021-09-23 올리패스 주식회사 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드
CN114502571B (zh) * 2019-07-18 2024-09-13 奥利通公司 黑素亲和素反义寡核苷酸
KR20210151593A (ko) 2020-06-05 2021-12-14 넥스올리고(주) 신규한 몰포리노 올리고뉴클레오티드 유도체
KR20240172540A (ko) * 2023-06-01 2024-12-10 주식회사 기프티드엠에스 세포 투과가 가능한 펩타이드-핵산 올리고머를 유효성분으로 포함하는 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물
KR102633299B1 (ko) 2023-09-08 2024-02-02 국방과학연구소 세포 투과가 가능한 펩타이드 핵산 올리고머를 유효성분으로 포함하는 한탄바이러스 감염 질환 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
US6617422B1 (en) * 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
DE10019136A1 (de) * 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
CN1814614A (zh) * 2005-02-06 2006-08-09 中国人民解放军军事医学科学院毒物药物研究所 核酸、肽核酸衍生物及它们的用途
US7960360B2 (en) 2006-11-13 2011-06-14 Jennifer Rubin Grandis Antisense guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents

Also Published As

Publication number Publication date
EP2268607B1 (en) 2015-02-18
IL207617A (en) 2016-07-31
AU2009224149A1 (en) 2009-09-17
WO2009113828A2 (en) 2009-09-17
CA2715844A1 (en) 2009-09-17
IL236513A0 (en) 2015-08-31
US20140155604A1 (en) 2014-06-05
CN102015628B (zh) 2015-04-22
CA2715844C (en) 2015-11-24
IL236515A0 (en) 2015-08-31
BRPI0906104A2 (pt) 2015-06-30
RU2564032C2 (ru) 2015-09-27
US20140155605A1 (en) 2014-06-05
DK2268607T3 (en) 2015-03-23
PT2268607E (pt) 2015-04-07
US20120040918A9 (en) 2012-02-16
KR101598423B1 (ko) 2016-03-02
PL2268607T3 (pl) 2015-09-30
MX2010009687A (es) 2010-12-21
ES2533769T3 (es) 2015-04-15
ZA201005960B (en) 2016-06-29
ES2533769T9 (es) 2016-05-13
US20140323728A1 (en) 2014-10-30
EP2268607B9 (en) 2015-05-13
US8895734B2 (en) 2014-11-25
US8680253B2 (en) 2014-03-25
WO2009113828A3 (en) 2009-12-23
DK2268607T5 (en) 2015-07-20
CN102015628A (zh) 2011-04-13
IL236514A0 (en) 2015-08-31
KR20110010691A (ko) 2011-02-07
US20110178031A1 (en) 2011-07-21
EP2268607A4 (en) 2013-11-13
HK1155717A1 (zh) 2012-05-25
AU2009224149B2 (en) 2013-01-24
KR20090098710A (ko) 2009-09-17
IL207617A0 (en) 2010-12-30
RU2010135635A (ru) 2012-03-10
JP5620282B2 (ja) 2014-11-05
JP2011518770A (ja) 2011-06-30
US8884008B2 (en) 2014-11-11
WO2009113828A9 (en) 2009-11-05
NZ587448A (en) 2012-03-30
BRPI0906104B1 (pt) 2021-03-30
US8859766B2 (en) 2014-10-14
EP2268607A2 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
BRPI0906104B8 (pt) derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
BRPI0613429A2 (pt) inibidores de histona desacetilase
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
WO2008112939A3 (en) Composition and method for making oligo-benzamide compounds
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
BRPI0812878B8 (pt) anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
BRPI0709598A8 (pt) composições de polipeptídeos estabilizados
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
WO2008019395A3 (en) Compounds for improving learning and memory
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
BR112012026147A2 (pt) espiroderivados azacíclicos como inibidores de hsl
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
NO20091999L (no) MAPK/ERK kinase inhibitorer
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
SV2008002512A (es) Derivados de aminoacidos ref. pc32769a
WO2006089168A3 (en) Methods for modulating ion channels
MX2008009830A (es) Efecto del inhibidor bst2.
DK2004149T3 (da) Farmaceutiske sammensætninger indeholdende leflunomid

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF